Alpha-Synuclein (α-Synuclein)

alpha-synuclein (alpha-synuclein)

Introduction

Alpha Synuclein (Α Synuclein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

alpha-synuclein is a presynaptic neuronal protein central to a group of disorders collectively called synucleinopathies, including Parkinson's disease, Lewy body dementia, [@braak2003]
and Multiple System Atrophy (MSA). Aggregated alpha-synuclein is a core component of Lewy bodies and Lewy neurites, placing it at the center of mechanistic models of selective [@luk2012]
neuronal vulnerability and progressive network dysfunction[@spillantini1998][@braak2003]. [@goedert2017]

As a disease mechanism, alpha-synuclein biology spans protein misfolding, oligomerization, fibril growth, cell-to-cell propagation, and inflammatory response. Research over the [@burre2010]
last decade has shifted from static inclusion-focused views toward dynamic models where strain-like conformers, cellular proteostasis capacity, and regional connectivity determine [@venda2010]
progression trajectories[@luk2012][@goedert2017]. [@mazzulli2011]

Physiological Function and Protein Homeostasis

...

alpha-synuclein (alpha-synuclein)

Introduction

Alpha Synuclein (Α Synuclein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

alpha-synuclein is a presynaptic neuronal protein central to a group of disorders collectively called synucleinopathies, including Parkinson's disease, Lewy body dementia, [@braak2003]
and Multiple System Atrophy (MSA). Aggregated alpha-synuclein is a core component of Lewy bodies and Lewy neurites, placing it at the center of mechanistic models of selective [@luk2012]
neuronal vulnerability and progressive network dysfunction[@spillantini1998][@braak2003]. [@goedert2017]

As a disease mechanism, alpha-synuclein biology spans protein misfolding, oligomerization, fibril growth, cell-to-cell propagation, and inflammatory response. Research over the [@burre2010]
last decade has shifted from static inclusion-focused views toward dynamic models where strain-like conformers, cellular proteostasis capacity, and regional connectivity determine [@venda2010]
progression trajectories[@luk2012][@goedert2017]. [@mazzulli2011]

Physiological Function and Protein Homeostasis

The SNCA gene encodes alpha-synuclein, a small intrinsically disordered protein enriched at presynaptic terminals. Under physiologic conditions, alpha-synuclein participates in synaptic vesicle cycling, membrane curvature sensing, and neurotransmitter release regulation. Its function depends on reversible transitions between soluble and membrane-associated conformations[@burre2010][@venda2010]. [@luk2012a]

Cellular quality-control pathways, including chaperone systems, autophagy-lysosomal flux, and ubiquitin-proteasome activity, normally limit pathogenic accumulation. Disruption of these pathways by aging, genetic variants, mitochondrial stress, or neuroinflammation can increase the pool of misfolded and aggregation-prone species[@venda2010][@mazzulli2011]. [@volpicellidaley2011]

Aggregation, Strains, and Propagation

A key pathogenic step is the conversion of native alpha-synuclein into beta-sheet-rich oligomers and fibrils. Evidence from neuropathology and experimental systems indicates that [@schweighauser2020]
seeded aggregation can spread through anatomically connected circuits, consistent with progressive staging patterns observed in human disease[@luk2012][@luk2012a]. In vivo inoculation studies in mice demonstrated that exogenous fibrils can trigger endogenous alpha and downstream [@yang2022]
dopaminergic injury[@luk2012a][@volpicellidaley2011]. [@singleton2003]

Structural studies further support mechanistic heterogeneity. Different fibril conformations have been resolved by cryo-EM and solid-state approaches, including tissue-derived structures from Lewy body disorders. These conformational differences may help explain why synucleinopathies vary by cell type, clinical phenotype, and progression speed[@schweighauser2020][@yang2022]. [@polymeropoulos1997]

alpha-synuclein Across Synucleinopathies

Parkinson's Disease

In Parkinson's disease, alpha is tightly linked to degeneration of dopaminergic neurons in the substantia nigra and associated motor/non-motor syndromes. Genetic forms involving SNCA multiplications or missense variants provide strong causal evidence that increased burden or altered conformation of alpha-synuclein drives disease biology[@singleton2003][@polymeropoulos1997]. [@walker2015]

Dementia with Lewy bodies

In Lewy body dementia, widespread cortical and limbic alpha contributes to cognitive fluctuation, hallucinations, and attentional deficits. Co-pathology with Alzheimer's disease features is common and can modify clinical expression[@spillantini1998][@walker2015]. [@krismer2017]

Multiple System Atrophy

Multiple System Atrophy (MSA) features alpha-synuclein-rich glial cytoplasmic inclusions in oligodendroglial lineages, illustrating that the same protein can generate disease in distinct cellular contexts. This reinforces the idea of disease-specific conformers and microenvironmental determinants[@goedert2017][@krismer2017]. [@hirsch2021]

Interactions with neuroinflammation and Cellular Stress

Misfolded alpha-synuclein is both a trigger and amplifier of innate immune signaling in microglia and astrocytes. Fibrillar and post-translationally modified alpha-synuclein species engage pattern-recognition pathways, drive cytokine release, and can sustain feed-forward injury loops that worsen synaptic and mitochondrial stress[@hirsch2021][@george2019][@tansey2024]. [@george2019]

Disease context matters: [@fujiwara2002]

• Parkinson's Disease: microglial activation frequently colocalizes with alpha-syn-rich regions and may shape progression kinetics via inflammasome and interferon-linked pathways.
• Dementia with Lewy bodies: post-mortem studies show neuroinflammatory burden that tracks with copathology and can modulate clinical expression, including cognitive fluctuation severity[@surendranathan2020][@rutherford2024].
• Multiple System Atrophy: oligodendroglial alpha-syn inclusions are coupled to pronounced glial inflammatory responses, supporting a distinct glia-dominant inflammatory topology versus neuron-predominant synucleinopathies[@vieira2019].

These differences are therapeutically relevant: anti-inflammatory interventions likely need disease-specific stratification rather than a single pan-synucleinopathy regimen. [@anderson2006]

Cross-Disease Immune Mechanisms: PD, DLB, and MSA

Mechanistic overlap exists across Parkinson's Disease, Lewy Body Dementia, and Multiple System Atrophy, but the dominant inflammatory context differs by cell-type involvement and aggregate compartmentalization. [@sardi2011]

• Parkinson's Disease (PD): microglial activation is tightly linked to alpha-synuclein species burden and appears to amplify neuronal stress through inflammasome-linked cytokine signaling and phagocytic dysregulation[@hirsch2021][@george2019][@tansey2024].
• Lewy Body Dementia (DLB): post-mortem and imaging-linked studies support a neuroinflammatory component that tracks with cortical network dysfunction and, in some cohorts, co-pathology burden[@surendranathan2020][@rutherford2024].
• Multiple System Atrophy (MSA): oligodendroglial alpha-synucleinopathy creates a distinct glial injury niche where myelin-associated stress and innate immune activation can be disproportionate to neuronal Lewy-body-centric patterns[@vieira2019].

These differences matter for translational design: a biomarker or immune-targeting strategy that performs in PD may not transfer directly to DLB or MSA without disease-specific enrichment and endpoint calibration. [@yaribash2025]

• [Proteins/ATP13A2](proteins/atp13a2) - Lysosomal ATPase affecting alpha-synuclein clearance
• [Proteins/FBXO7](proteins/fbxo7) - F-box protein in parkin-mediated mitophagy
• [Proteins/CTSD](proteins/ctsd-protein) - Lysosomal protease in alpha-synuclein degradation

Therapeutic Approaches

Multiple biotechnology companies are developing therapies targeting alpha-synuclein pathology:

Immunotherapies

• AC Immune — ACI-35 liposomal tau vaccine (also targets alpha-synuclein)
• Vaxxinity — VX15 alpha-synuclein vaccine
• Prothena — PRX002 (prasinezumab) anti-alpha-synuclein antibody
• UCB Pharma — UCB0599 alpha-synuclein misfolding inhibitor

Small Molecule Inhibitors

• Gain Therapeutics — GCase modulators targeting alpha-synuclein aggregation
• Denali Therapeutics — LRRK2 inhibitors may reduce alpha-synuclein phosphorylation

Gene Therapy

• Prevail Therapeutics — GBA1 gene therapy for PD (targets alpha-synuclein dysregulation)

See the PD Pipeline Companies index for clinical trial status and latest development updates.

Recent Research Updates (2024-2026)

Recent advances in alpha-synuclein research have revealed novel insights into structure, propagation mechanisms, and therapeutic targeting:

• Cryo-EM structures of alpha-synuclein filaments: High-resolution cryo-EM studies have identified novel filament subtypes in Multiple System Atrophy (MSA), revealing strain-specific structural differences that may explain the distinct clinical phenotypes of synucleinopathies[@schweighauser2024].
• RNA G-quadruplexes as aggregation scaffolds: Research demonstrates that RNA G-quadruplexes form scaffolds that promote neuropathological alpha-synuclein aggregation, providing new targets for therapeutic intervention in Parkinson's disease[@matsuo2024].
• alpha-Synuclein pathology as therapeutic target: Comprehensive reviews highlight emerging disease-modifying strategies targeting alpha-synuclein aggregation, including small molecule inhibitors, immunotherapy, and gene therapy approaches[@park2024].
• Gut-brain propagation pathways: Studies on gut-induced alpha-synuclein and tau propagation have revealed mechanisms by which peripheral pathology initiates neurodegeneration in the central nervous system, supporting the Braak hypothesis and identifying novel intervention points[@xiang2024].
• Immunotherapy clinical updates: Recent clinical trials of immune-based alpha-synuclein therapies have shown promise in modifying disease progression, with active and passive immunization strategies advancing through clinical development[@alfaidi2024].
• alpha-Synuclein biomarkers for Parkinson's disease: A comprehensive 2026 review by Lodge and Agin-Liebes provides an updated overview of alpha-synuclein biomarkers including CSF and blood-based assays, PET ligands, and seeding assays (RT-QuIC, PMCA) for PD diagnosis and progression monitoring[@lodge2026].
• Glymphatic system targeting: Novel therapeutic strategies targeting the glymphatic system to promote alpha-synuclein clearance represent a promising new approach for PD treatment[@lian2026].

See Also

• Parkinson's disease - The primary disease associated with alpha
• Lewy body dementia - Another synucleinopathy characterized by Lewy bodies
• multiple system atrophy - A neurodegenerative synucleinopathy with oligodendroglial pathology
• Dementia with Lewy Bodies - Parkinsonism with cognitive fluctuations and visual hallucinations
• Synucleinopathies - Overview of diseases characterized by alpha

External Links

• [UniProt: alpha-synuclein (P37840)](https://www.uniprot.org/uniprotkb/P37840/entry)
• [OMIM: SNCA (163890)](https://omim.org/entry/163890)
• [NCBI Gene: SNCA](https://www.ncbi.nlm.nih.gov/gene/6622)
• [PDGene Database](https://www.pdgene.org/) - Parkinson's Disease genetic data

<!-- ci040-visuals:alpha-synuclein-aggregation --> [@siderowf2023]

Visual Summary

Pathway Flowchart

SVG Diagram

!alpha-synuclein-aggregation pathway diagram [@shahnawaz2020]

Figure: alpha synuclein aggregation pathway schematic generated for NeuroWiki. [@tansey2024]

Background

The study of Alpha Synuclein (Α Synuclein) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@vieira2019]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@surendranathan2020]

Additional evidence sources: [@rutherford2024]

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 27 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 44%

References

[Spillantini et al., alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9600990/)

[Braak et al., Staging of brain pathology related to sporadic Parkinson's Disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12796765/)

[Luk et al., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/23161999/)

[Goedert et al., Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28259760/)

[Burre et al., alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20395379/)

[Venda et al., alpha-synuclein and dopamine at the crossroads of Parkinson's Disease (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20012576/)

[Mazzulli et al., Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22078885/)

[Luk et al., Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22508839/)

[Volpicelli-Daley et al., Exogenous alpha-synuclein fibrils induce Lewy body pathology in cultured neurons (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21982369/)

[Schweighauser et al., Structures of alpha-synuclein filaments from Multiple System Atrophy (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32499608/)

[Yang et al., Structure of alpha-synuclein fibrils derived from human Lewy Body Dementia tissue (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36711931/)

[Singleton et al., alpha-synuclein locus triplication causes Parkinson's Disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12673283/)

[Polymeropoulos et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's Disease (1997) (1997)](https://pubmed.ncbi.nlm.nih.gov/9054604/)

[Walker et al., Lewy body dementias (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25676544/)

[Unknown, Krismer and Wenning, Multiple System Atrophy: insights into a rare and debilitating movement disorder (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/27802287/)

[Unknown, Hirsch and Standaert, Ten unsolved questions about neuroinflammation in Parkinson's Disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34534678/)

[George et al., Microglia in Parkinson's Disease and alpha-synucleinopathies (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31300776/)

[Fujiwara et al., alpha-synuclein is phosphorylated in synucleinopathy lesions (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12446719/)

[Anderson et al., Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16847063/)

[Sardi et al., CNS expression of glucocerebrosidase corrects alpha and memory in a model of Gaucher-related synucleinopathy (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21820160/)

[Yaribash et al., alpha-synuclein Pathophysiology in Neurodegenerative Disorders: a review of mechanisms and treatment advances (2025) (2025)](https://pubmed.ncbi.nlm.nih.gov/40140103/)

[Siderowf et al., Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36815437/)

[Shahnawaz et al., Discriminating alpha-synuclein strains in Parkinson's Disease and Multiple System Atrophy (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32094116/)

[Tansey et al., The immune system in Parkinson's Disease: what we know so far (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38833182/)

[Vieira et al., Oligodendroglial alpha-synucleinopathy-driven neuroinflammation in Multiple System Atrophy (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30444295/)

[Surendranathan et al., neuroinflammation in dementia with Lewy bodies: a human post-mortem study (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32747635/)

[Rutherford et al., neuroinflammation is associated with Alzheimer's Disease co-pathology in dementia with Lewy bodies (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38715119/)

[Schweighauser et al., Cryo-EM structure of a novel alpha-synuclein filament subtype from multiple system atrophy (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39511911/)

[Matsuo et al., RNA G-quadruplexes form scaffolds that promote neuropathological alpha-synuclein aggregation (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39426376/)

[Park et al., alpha-Synuclein pathology as a target in neurodegenerative diseases (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39609631/)

[Xiang et al., Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39241780/)

[Alfaidi et al., An update on immune-based alpha-synuclein trials in Parkinson's disease (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39666171/)